Moreover, CD123 expression was enhanced by FLT3 mutations, suggesting that the subset of NPM1/FLT3 double-mutated AML patients could particularly benefit from anti-CD123 targeted therapies [107]. This evidence concerns the gene FLT3 and acute myeloid leukemia.